Lisata Therapeutics, Inc. Common Stock (LSTA) Stock Price

LSTAStock

$1.69−28.09%52W

Market Cap$15.23M

P/E—

PEG Ratio—

Div yield—

Beta0.98

LSTA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-73.52%

Price vs S&P 500 (4W)60.96%

VGM Score32.19

Book Value / Share (Quarterly)$1.20

P/TBV (Annual)1.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-78.84%

Cash Flow / Share (Quarterly)$-1.50

Price vs S&P 500 (YTD)-21.96%

Gross Margin (TTM)9.52%

Net Profit Margin (TTM)-4478.24%

EPS (TTM)$-1.91

10-Day Avg Trading Volume0.91M

EPS Excl Extra (TTM)$-1.91

Revenue Growth (5Y)-58.81%

EPS (Annual)$-1.91

ROI (Annual)-111.65%

Gross Margin (Annual)9.56%

Net Profit Margin (5Y Avg)-2537.24%

Cash / Share (Quarterly)$1.43

Revenue Growth QoQ (YoY)-90.00%

ROA (Last FY)-93.47%

Revenue Growth TTM (YoY)-27.06%

EBITD / Share (TTM)$-2.08

ROE (5Y Avg)-66.74%

Operating Margin (TTM)-4674.71%

Cash Flow / Share (Annual)$-1.81

P/B Ratio0.96x

P/B Ratio (Quarterly)4.14x

Net Income / Employee (Annual)$-789,800

Net Interest Coverage (TTM)-1616.00x

ROA (TTM)-70.85%

EPS Incl Extra (Annual)$-1.91

Current Ratio (Annual)5.76x

Quick Ratio (Quarterly)3.94x

3-Month Avg Trading Volume0.20M

52-Week Price Return-28.09%

Revenue / Employee (TTM)$8,100

Tangible BV / Share (Quarterly)$1.68

P/S Ratio (Annual)61.49x

Asset Turnover (Annual)0.01x

52-Week High$5.07

Operating Margin (5Y Avg)-2806.21%

EPS Excl Extra (Annual)$-1.91

CapEx CAGR (5Y)6.96%

Tangible BV CAGR (5Y)5.57%

26-Week Price Return-61.59%

Quick Ratio (Annual)5.20x

13-Week Price Return-48.79%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.23x

Enterprise Value$-2.61M

Revenue / Share Growth (5Y)-83.48%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-36.18%

Revenue / Employee (Annual)$8,100

Inventory Turnover (Annual)0.82x

Pretax Margin (Annual)-10322.35%

Cash / Share (Annual)$1.81

3-Month Return Std Dev139.49%

Gross Margin (5Y Avg)11.85%

Net Income / Employee (TTM)$-789,800

ROE (Last FY)-111.65%

Net Interest Coverage (Annual)-71.89x

EPS Basic Excl Extra (Annual)$-1.91

P/FCF (TTM)2.33x

Receivables Turnover (TTM)0.38x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.91

Receivables Turnover (Annual)0.38x

ROI (TTM)-84.39%

P/S Ratio (TTM)61.49x

Pretax Margin (5Y Avg)-2682.23%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$1.68

Price vs S&P 500 (52W)-46.64%

Year-to-Date Return-9.14%

5-Day Price Return-3.98%

EPS Normalized (Annual)$-1.91

ROA (5Y Avg)-58.26%

Net Profit Margin (Annual)-9756.47%

Month-to-Date Return70.71%

Cash Flow / Share (TTM)$-2.66

EBITD / Share (Annual)$-2.08

Operating Margin (Annual)-10711.18%

LT Debt / Equity (Annual)0.55x

ROI (5Y Avg)-66.74%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.91

P/TBV (Quarterly)1.10x

P/B Ratio (Annual)1.10x

Inventory Turnover (TTM)1.23x

Pretax Margin (TTM)-4478.24%

Book Value / Share (Annual)$1.68

Price vs S&P 500 (13W)-50.74%

Beta0.98x

P/FCF (Annual)10.35x

Revenue / Share (TTM)$0.02

ROE (TTM)-84.39%

52-Week Low$0.99

vGradeB

gGradeF

mGradeD

vgmGradeD

LSTA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 6, 2025	-$0.54	-$0.49	+8.41%(+$0.05)
Q2 2025	Aug 7, 2025	-$0.65	-$0.54	+16.92%(+$0.11)
Q1 2025	May 8, 2025	-$0.53	-$0.55	-3.77%(-$0.02)

LSTA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

4.00

3.89

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
LSTALisata Therapeutics, Inc. Common Stock	B	F	D	$1.69
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Lisata Therapeutics, Inc. Common Stock

Lisata Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for solid tumors. Its lead candidate, certepetide, is designed to activate a proprietary uptake pathway that enhances the ability of co-administered anti-cancer drugs to penetrate and target solid tumors more effectively.